Proteins and Peptides

11 May 2017 SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection
10 May 2017 Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
09 May 2017 Molecular Partners’ strategic partner Allergan completed patient recruitment in both abicipar pegol nAMD Phase 3 studies
08 May 2017 Araim Pharmaceuticals' Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis
05 May 2017 Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery
04 May 2017 Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of Obesity
03 May 2017 NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
03 May 2017 BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
03 May 2017 Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection
03 May 2017 Bonti Announces Hot Topics Presentation of Phase 2a Interim Clinical Data at The Aesthetic Meeting 2017
03 May 2017 ImmunGene Regains Antibody-Interferon Fusion Product Candidates from Valor Biotherapeutics
03 May 2017 Stealth BioTherapeutics Initiates Phase 1/2 Trial of SBT-20 in Patients With Early Stage Huntington's Disease
02 May 2017 Ampio Initiates Pivotal Trial of Ampion
02 May 2017 Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
02 May 2017 Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex™ Did Not Achieve its Primary Endpoint
28 Apr 2017 FDA Approves Radius Health’s TYMLOS™ (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
28 Apr 2017 Novo Nordisk Receives FDA Approval of Saxenda® (liraglutide) injection 3 mg Label Update Including Long-Term Safety and Efficacy Data from 3-Year Trial
28 Apr 2017 FDA Approves Brineura™ (cerliponase alfa) for the Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare Pediatric Brain Disorder in Children
28 Apr 2017 Bonti Announces Inaugural Presentation of Phase 2a Clinical Data for Its Lead Product EB-001
27 Apr 2017 Ra Pharmaceuticals Initiates Dosing of RA101495 in PNH Patients
26 Apr 2017 Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism
22 Apr 2017 BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children
22 Apr 2017 NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
22 Apr 2017 Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
20 Apr 2017 First Patient in Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top